Roivant Sciences Q4 2024 GAAP EPS $(0.19) Beats $(0.32) Estimate, Sales $28.930M Miss $32.101M Estimate

5/30/24 7:02:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ROIV alert in real time by email

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.32) by 40.63 percent. The company reported quarterly sales of $28.930 million which missed the analyst consensus estimate of $32.101 million by 9.88 percent. This is a 5.68 percent increase over sales of $27.376 million the same period last year.

Get the next $ROIV alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ROIV

Date	Price Target	Rating	Analyst
3/20/2026	$35.00	Outperform	Bernstein
9/2/2025	$16.00	Buy	Citigroup
7/10/2025	$19.00	Buy	Goldman
2/15/2024	$17.00	Outperform	Wolfe Research
1/5/2024	$20.00	Overweight	Piper Sandler
12/12/2023	$14.00	Buy	Deutsche Bank
10/17/2023	$17.00	Buy	Guggenheim
6/8/2023	$10.50	Neutral	BofA Securities

More analyst ratings

$ROIV
Press Releases

Fastest customizable press release news feed in the world

View All

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its

4/2/26 5:00:00 AM ET

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

4/2/26 5:00:00 AM ET

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reductionAdditional analyses from VALOR, presented at the 2026 American Academy of Dermatology (AAD) Meeting, demonstrated meaningful improvements in itch and skin-related quality of life with brepocitinib 30 mgThe U.S. Fo

3/28/26 3:00:00 PM ET

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

$ROIV
Leadership Updates

Live Leadership Updates

View All

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

3/26/24 6:22:00 PM ET

$PGTI

$ROIV

$RUN

Building Products

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

11/10/23 8:00:00 AM ET

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

10/13/23 8:00:00 AM ET

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

4/2/26 5:00:00 AM ET

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

3/3/26 4:15:00 PM ET

$ABUS

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

3/3/26 4:15:00 PM ET

$ABUS

$ROIV

Biotechnology: Pharmaceutical Preparations

Health Care

Roivant Sciences Q4 2024 GAAP EPS $(0.19) Beats $(0.32) Estimate, Sales $28.930M Miss $32.101M Estimate

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ROIV

Roivant Sciences Q4 2024 GAAP EPS $(0.19) Beats $(0.32) Estimate, Sales $28.930M Miss $32.101M Estimate

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ROIV

$ROIV
SEC Filings

Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

SEC Form 144 filed by Roivant Sciences Ltd.

$ROIV
Press Releases

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

$ROIV
Insider Trading

SEC Form 4 filed by Torti Frank

SEC Form 4 filed by Gline Matthew

SEC Form 4 filed by Sukhatme Mayukh

$ROIV
Analyst Ratings

Bernstein initiated coverage on Roivant Sciences with a new price target

Citigroup initiated coverage on Roivant Sciences with a new price target

Goldman resumed coverage on Roivant Sciences with a new price target

$ROIV
Insider Purchases

CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

$ROIV
Leadership Updates

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

$ROIV
Financials

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

$ROIV
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

SEC Form SC 13G filed by Roivant Sciences Ltd.

Roivant Sciences Q4 2024 GAAP EPS $(0.19) Beats $(0.32) Estimate, Sales $28.930M Miss $32.101M Estimate

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ROIV

Roivant Sciences Q4 2024 GAAP EPS $(0.19) Beats $(0.32) Estimate, Sales $28.930M Miss $32.101M Estimate

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ROIV

$ROIV SEC Filings

Roivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

SEC Form 144 filed by Roivant Sciences Ltd.

$ROIV Press Releases

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

$ROIV Insider Trading

SEC Form 4 filed by Torti Frank

SEC Form 4 filed by Gline Matthew

SEC Form 4 filed by Sukhatme Mayukh

$ROIV Analyst Ratings

Bernstein initiated coverage on Roivant Sciences with a new price target

Citigroup initiated coverage on Roivant Sciences with a new price target

Goldman resumed coverage on Roivant Sciences with a new price target

$ROIV Insider Purchases

CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

$ROIV Leadership Updates

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

$ROIV Financials

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

$ROIV Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

SEC Form SC 13G filed by Roivant Sciences Ltd.

Recent Analyst Ratings for
$ROIV

Recent Analyst Ratings for
$ROIV

$ROIV
SEC Filings

$ROIV
Press Releases

$ROIV
Insider Trading

$ROIV
Analyst Ratings

$ROIV
Insider Purchases

$ROIV
Leadership Updates

$ROIV
Financials

$ROIV
Large Ownership Changes